Rongchang Biotech (688331.SH) released its 2023 annual report. The company achieved operating income of 10 during the reporting period...
According to Zhitong Finance App, Rongchang Biotech (688331.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 1,083 billion yuan, an increase of 40.26%; net loss attributable to shareholders of listed companies was 1,511 billion yuan, an increase in year-on-year losses; net loss attributable to shareholders of listed companies after deducting non-recurring gains and losses was 1,543 billion yuan, an increase in year-on-year losses; and a basic loss per share was 2.80 yuan/share.
During the reporting period, operating income increased by 40.26% year on year, mainly due to the increase in sales of the company's titacip and viducitumab this year; net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses year-on-year decreased, mainly due to the continuous advancement of various R&D pipelines this year, several innovative drugs in the critical testing and research stage, and a significant increase in R&D expenses, as well as an increase in commercial sales investment team building expenses and academic promotion activities.